U of M study shows why treatment isn't effective for HIV

Key points
- University of Minnesota researchers have answered a key question as to why antiretroviral therapy isn't effective in restoring immunity in HIV-infected patients.
- Once a person is infected with the virus, fibrosis, or scarring, occurs in the lymph nodes – the home of T cells that fight infection.
- "Importantly, we discovered that this fibrosis occurs more rapidly and to a greater extent in the portion of the gut – the largest lymphatic tissue in the body – containing the T cells, compared with other immune tissues," he said.
- The results of the study, sponsored by the National Institute of Health, will be published in the Aug.
New research shows scarring occurs quickly in gut, limiting drug effectiveness
University of Minnesota researchers have answered a key question as to why antiretroviral therapy isn't effective in restoring immunity in HIV-infected patients.
Once a person is infected with the virus, fibrosis, or scarring, occurs in the lymph nodes – the home of T cells that fight infection. And once fibrosis occurs, T cells can't repopulate the lymph nodes when HIV therapy begins, said Timothy Schacker, M.D., professor of medicine and principal investigator on the study.
"Importantly, we discovered that this fibrosis occurs more rapidly and to a greater extent in the portion of the gut – the largest lymphatic tissue in the body – containing the T cells, compared with other immune tissues," he said. "The fibrosis stops cells from returning to immune tissues, especially in the gut."
The results of the study, sponsored by the National Institute of Health, will be published in the Aug. 15 edition of the Journal of Infectious Disease. The article is currently online.
In the study, seven HIV-infected patients were treated very early after infection and experienced a greater degree of immune reconstitution than patients treated in the chronic or end stages of the disease, especially in the gut.
Schacker said it's crucial to start therapy earlier than current guidelines suggest. Beginning in the earliest stages of infection, when the patient only shows preliminarily symptoms of HIV, can preserve some elements of the immune system (mainly protecting T-cells that fight infection), he said.
The research also suggests that anti-fibrotic drugs might have a role as adjunctive therapy in HIV-1 infections – both in limiting depletion and improving reconstitution of T cells under therapy.
###
Contact: Nick Hanson
hans2853@umn.edu
612-624-2449
University of Minnesota
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Infections, HIV & STIs →
NewsDelaying treatment for hepatitis C puts patients' lives at risk
Data revealed today at The International Liver Congress™ 2015 highlights the impact of delaying treatment for the hepatitis C virus (HCV). Researchers found that treatment delays have a serious detrimental effect on…
24 April 2015
NewsCochrane Review of effectiveness of point of care diagnostics for schistosomiasis
Researchers from the Cochrane Infectious Disease Group, hosted at LSTM, have conducted an independent review to assess how well point of care tests detect Schistosoma infections in people living in endemic regions.…
12 March 2015
NewsStudy shows how Ebola becomes lethal as it spreads
Scientists investigated why Ebola virus is so deadly when it spreads from animals to humans and then from human-to-human contact. The research team looked at the Zaire Ebola strain in an animal system to understand how…



